

18. B. J. Buchwitz, K. Ahmad, L. L. Moore, M. B. Roth, S. Henikoff, *Nature* **401**, 547 (1999).
19. R. Kitagawa, A. M. Rose, *Nature Cell Biol.* **1**, 514 (1999).
20. K. G. Hardwick, R. C. Johnston, D. L. Smith, A. W. Murray, *J. Cell Biol.* **148**, 871 (2000).
21. S. S. Taylor, E. Ha, F. McKeon, *J. Cell Biol.* **142**, 1 (1998).
22. Materials and methods are available as supplementary material on Science Online.
23. T. Fukushige, M. J. Hendzel, D. P. Bazett-Jones, J. D. McGhee, *Proc. Natl. Acad. Sci. U.S.A.* **96**, 11883 (1999).
24. R. M. Douglas, G. G. Haddad, *J. Appl. Physiol.* **94**, 2068 (2003).
25. The authors would like to thank T. Record and M. Capp for providing LacI repressor protein, J. McGhee for providing tagged nematode strain jm93, S. Biggins and B. Buchwitz for critical reading of the manuscript, J. Stear for advice and technical assistance, T. Stier-nagle for providing nematode strains, and J. Ahringer and the Owning Organisation and Scientist and Distributing Organisation for making the Chromosome I RNAi Library available. Funding for this work was provided by NIH grant GM48435 to M.R. T.G.N. is supported by National Research Service award T32

GM07270, J.P.G. is supported by an NSF Graduate Research Fellowship, and P.A.P. is supported by NSF Postdoctoral Fellowship 0112253, NSF Research Starter grant 0307491, and a University of North Texas Health Science Center American Cancer Society Institutional Research grant.

#### Supporting Online Material

www.sciencemag.org/cgi/content/full/302/5647/1038/DC1

Materials and Methods  
Table S1

28 July 2003; accepted 22 September 2003

## Control of Effector CD8<sup>+</sup> T Cell Function by the Transcription Factor *Eomesodermin*

Erika L. Pearce,<sup>1</sup> Alan C. Mullen,<sup>1</sup> Gislaine A. Martins,<sup>1</sup> Connie M. Krawczyk,<sup>1</sup> Anne S. Hutchins,<sup>1</sup> Valerie P. Zediak,<sup>1</sup> Monica Banica,<sup>1</sup> Catherine B. DiCioccio,<sup>1</sup> Darrick A. Gross,<sup>1</sup> Chai-an Mao,<sup>4</sup> Hao Shen,<sup>2</sup> Nezh Cereb,<sup>5</sup> Soo Y. Yang,<sup>5</sup> Tullia Lindsten,<sup>1</sup> Janet Rossant,<sup>4</sup> Christopher A. Hunter,<sup>3</sup> Steven L. Reiner<sup>1\*</sup>

Activated CD8<sup>+</sup> T cells play a critical role in host defense against viruses, intracellular microbes, and tumors. It is not clear if a key regulatory transcription factor unites the effector functions of CD8<sup>+</sup> T cells. We now show that *Eomesodermin* (*Eomes*), a paralogue of *T-bet*, is induced in effector CD8<sup>+</sup> T cells in vitro and in vivo. Ectopic expression of *Eomes* was sufficient to invoke attributes of effector CD8<sup>+</sup> T cells, including interferon- $\gamma$  (IFN- $\gamma$ ), perforin, and granzyme B. Loss-of-function analysis suggests *Eomes* may also be necessary for full effector differentiation of CD8<sup>+</sup> T cells. We suggest that *Eomesodermin* is likely to complement the actions of *T-bet* and act as a key regulatory gene in the development of cell-mediated immunity.

Emerging evidence suggests that the functional development of distinct T cell lineages is directed by key, or “master,” regulatory transcription factors, which have the capacity to impart the defining attributes of a lineage (1–8). *T-bet* is a member of the T-box family of genes responsible for controlling lineage commitment in T helper 1 (T<sub>H</sub>1) cells (2–5). CD4<sup>+</sup> T cells and natural killer (NK) cells from *T-bet*-deficient mice are defective in their ability to express IFN- $\gamma$ , although CD8<sup>+</sup> T cells from *T-bet*-deficient mice reportedly can exhibit normal IFN- $\gamma$  induction and cytolytic function (3). This implies the existence of a *T-bet*-independent pathway for effector differentiation of CD8<sup>+</sup> T cells.

To further examine this, we tested the

effect of a dominant negative form of *T-bet* (DN *T-bet*) on the differentiation of CD8<sup>+</sup> T cells. The DN *T-bet* construct, which contains the *Drosophila* engrailed repression domain in place of the endogenous trans-activation domain, inhibits Th1 differentiation (5, 9) in a manner similar to *T-bet* gene deletion (3). In light of the reported *T-bet*-independent expression of IFN- $\gamma$  from CD8<sup>+</sup> T cells (3), the profound defect in IFN- $\gamma$  expression resulting from introduction of DN *T-bet* retrovirus (RV) into activated CD8<sup>+</sup> T cells was unexpected (Fig. 1A). Consistent with prior studies of *T-bet* deficiency (3), we found that CD8<sup>+</sup> T cells from a newly generated line of *T-bet*-deficient mice (10) also exhibit only minimal defect in their ability to express IFN- $\gamma$  (Fig. 1A). Despite the absence of detectable *T-bet* activity in cells of *T-bet*<sup>-/-</sup> mice, DN *T-bet* was nevertheless able to antagonize the expression of IFN- $\gamma$  in CD8<sup>+</sup> T cells from these animals (Fig. 1A). These results reveal a *T-bet*-independent, but DN *T-bet*-sensitive, pathway for IFN- $\gamma$  induction in CD8<sup>+</sup> T cells.

The apparent antagonism of IFN- $\gamma$  induction by DN *T-bet*, in the absence of

*T-bet*, suggested the existence of an additional T-box factor in CD8<sup>+</sup> T cells that might control the expression of IFN- $\gamma$ . We, therefore, used degenerate oligonucleotides complementary to a highly conserved portion of the T-box (DNA binding) region to amplify cDNA from activated CD8<sup>+</sup> T cells (9). Of 18 cloned and sequenced amplicons, 8 encoded *T-bet*; the other 10 encoded *Eomesodermin* (Fig. 1B). *Eomesodermin* (*Eomes*) is a T-box factor that plays a key regulatory role in initiating mesodermal cell fate in most vertebrates (11) and has an additional role in mammalian trophoblast differentiation (12). *Eomes*<sup>-/-</sup> mice die early in embryogenesis (12). Phylogenetic and sequence analysis has placed *Eomes* and *T-bet* within the same subfamily of T-box factors (13, 14), and amino acid alignment (9) reveals that *Eomes* and *T-bet* are 74% identical in their T-box regions (Fig. 1B).

Because it was unknown whether *Eomes* is expressed in the immune system (12), we first examined expression of *Eomes* and *T-bet* in activated T cell subsets. Using sequences from their divergent amino termini (Fig. 1B), we developed specific molecular probes that could distinguish the related *Eomes* and *T-bet* transcripts (9). Although both activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells expressed *T-bet* (Fig. 1C), as previously reported (2, 3), significant induction of *Eomes* mRNA was restricted to activated CD8<sup>+</sup> T cells. Low, but detectable, amounts of *Eomes* mRNA were evident in naive CD8<sup>+</sup> T cells from normal mice (Fig. 1C) and in purely enriched naive populations obtained from recombination-deficient T cell receptor (TCR) transgenic T cells (15). To further explore the function of *Eomes* within the CD8<sup>+</sup> population, we constructed a DN *Eomes* RV, in a manner analogous to DN *T-bet*, by replacing the carboxy-terminal trans-activation domain of *Eomes* with the *Drosophila* engrailed repression domain (9). DN *Eomes* displayed equivalent effects to DN *T-bet* in inhibiting IFN- $\gamma$  induction in wild-type (Fig. 1D) and *T-bet*-deficient (9) CD8<sup>+</sup> T cells. Specificity was further confirmed by the findings that the most closely related T-box factor to *Eomes* and *T-bet* is not expressed in CD8<sup>+</sup> T cells and that a DN form

<sup>1</sup>Abramson Family Cancer Research Institute, and Department of Medicine, <sup>2</sup>Department of Microbiology, <sup>3</sup>Department of Pathobiology, University of Pennsylvania, Philadelphia, PA 19104, USA. <sup>4</sup>Samuel Lunenfeld Research Institute, and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada M5G 1X5. <sup>5</sup>Histogenetics, and Center for Genetic Polymorphism, Ossining, NY 10562, USA.

\*To whom correspondence should be addressed. E-mail: sreiner@mail.med.upenn.edu

## REPORTS


of a more distantly related T-box factor had little effect on IFN- $\gamma$  induction in CD8 $^+$  T cells (9). Together, these findings suggested that Eomes may be required for T-bet-independent IFN- $\gamma$  induction in CD8 $^+$  T cells.

To further evaluate the function of Eomes in differentiation, we constructed a RV containing the entire coding region of the gene (9). When


introduced in developing T $_H2$  cells, which are nonpermissive for expression of T-bet (2, 4) or Eomes (15), both T-bet and Eomes RV mediated substantial induction of IFN- $\gamma$  (Fig. 1E). Under these conditions, Eomes and T-bet RV did not appear to repress interleukin 4 (IL-4) expression (15). The apparent rescue of IFN- $\gamma$  expression by either T-box factor was also ev-

ident when cross-linking CD3-specific antibody was used for restimulation instead of chemical mitogens (9). We also found that Eomes RV was sufficient to induce effector function independently of T-bet, by rescuing IFN- $\gamma$  expression in *T-bet* $^{-/-}$  CD4 $^+$  T cells (9). Finally, the full-length Eomes RV also allowed us to test our original hypothesis that

**Fig. 1.** Eomesodermin mediates T-bet-independent IFN- $\gamma$  induction. **(A)** DN T-bet antagonizes IFN- $\gamma$  expression in CD8 $^+$  T cells. CD4-depleted splenocytes from *T-bet* $^{+/+}$  and *T-bet* $^{-/-}$  B6  $\times$  129 mice were stimulated for 24 hours and then transduced with either control (empty) human nerve growth factor receptor (hNGFR) RV or DN T-bet hNGFR RV (9). Cells were recultured for an additional 3 days before analysis of CD8, hNGFR, and IFN- $\gamma$  expression by flow cytometry. Only CD8 $^+$  events are shown. Numbers indicate percentage of transduced, CD8 $^+$  cells expressing IFN- $\gamma$ . **(B)** Major domains of the paralogues, T-bet and Eomes. Amino-terminus (N), DNA-binding domain (T-box), and carboxy-terminal trans-activation domain (C), plus percent identities are indicated. **(C)** Eomes is expressed in activated CD8 $^+$  T cells. Naive CD4 $^+$  ("4") and CD8 $^+$  ("8") T cells from the spleens of normal mice were examined directly (left) or activated for 3 days (right) before sequential Northern analysis with specific probes for Eomes, T-bet, and  $\beta$ -actin. **(D)** DN Eomes antagonizes IFN- $\gamma$  expression in CD8 $^+$  T cells. CD4-depleted splenocytes from wild-type (*T-bet* $^{+/+}$ ) B6  $\times$  129 mice were stimulated for 24 hours, and then transduced with designated green fluorescent protein (GFP) RV. Cells were recultured for an additional 6 days before analysis of CD8, GFP, and IFN- $\gamma$  expression by flow cytometry. Only GFP $^+$ CD8 $^+$  events are shown. Numbers indicate percentage of transduced, CD8 $^+$  cells expressing IFN- $\gamma$ . Identical results were obtained



with *T-bet* $^{-/-}$  mice (9). **(E)** Eomes is sufficient to induce IFN- $\gamma$  expression in developing T $_H2$  cells. CD8-depleted BALB/c splenocytes were stimulated in T $_H2$  conditions for 24 hours, and then transduced with control GFP RV, T-bet GFP RV, or Eomes GFP RV. Each group was co-transduced with control (empty) hNGFR RV. Cells were recultured in T $_H2$  conditions for an additional 8 days before analysis of hNGFR, GFP, and IFN- $\gamma$  expression. Numbers indicate percentage of transduced cells expressing IFN- $\gamma$ . All results are representative of at least two separate experiments.



**Fig. 2.** Eomesodermin may be critical for cytolytic gene expression and function. **(A)** Eomes is coordinately regulated with lytic gene expression in lymphokine-activated natural killer (LAK) cells and cytotoxic T cells. LAK cells were prepared from the bone marrow of C57BL/6 lymphocyte-deficient mice by using human recombinant IL-2 (9) and compared with C57BL/6 CD4 $^+$  and CD8 $^+$  T cells that were activated for 3 days before RNA extraction and sequential Northern analysis with specific probes for Eomes, T-bet, perforin, granzyme B, and  $\beta$ -actin. **(B)** Eomes is expressed in activated CD8 $^+$  T cells as part of the antiviral response in vivo. C57BL/6 mice were infected intraperitoneally with  $2 \times 10^5$  plaque-forming units Armstrong strain of LCMV. On day 6 postinfection, CD4 $^+$  and CD8 $^+$  T cells were isolated before RNA extraction and sequential Northern analysis with specific probes for Eomes and  $\beta$ -actin. Groups from infected mice are compared with CD8 $^+$  T cells from unchallenged controls. **(C)** DN Eomes antagonizes T-bet-dependent and T-bet-independent granzyme B expression. CD4-depleted splenocytes from *T-bet* $^{+/+}$  (dark gray filled plot and line plots) and *T-bet* $^{-/-}$  (light gray filled plot and black line plots) B6  $\times$  129 mice were stimulated for 24 hours, and then transduced with control (Ctrl) GFP RV (filled histograms),

DN Eomes (Eo) GFP RV (solid lines), or DN T-bet (Tb) GFP RV (dashed lines). Cells were recultured for an additional 5 days before analysis of CD8, GFP, and granzyme B expression by flow cytometry. Only CD8 $^+$ GFP $^+$  events are shown. Relative to *T-bet* $^{+/+}$  cells with control RV, the reduction in mean fluorescence intensity for each group (genotype and RV) was:  $-/-$  Ctrl, 1.4-fold;  $+/+$  DN Eo, 2.0-fold;  $-/-$  DN Eo, 2.2-fold;  $+/+$  DN Tb, 2.1-fold;  $-/-$  DN Tb, 2.4-fold. **(D)** DN Eomes antagonizes cytolytic function. Transgenic T cells specific for LCMV were transduced with control GFP or DN Eomes GFP RV 24 hours after stimulation with peptide and antigen-presenting cells. Cells were recultured for an additional 5 days and sorted for expression of GFP and CD8. After overnight rest, these effector cells were used at the indicated ratios with peptide-pulsed or unpulsed targets. Percent cytotoxicity was measured with a standard methodology (9). **(E)** Eomes may be necessary for full effector CD8 $^+$  T cell development. Splenocytes from *Eomes* $^{+/+}$  and *Eomes* $^{+/-}$  littermates were stimulated for 3 days before RNA extraction and sequential Northern analysis with specific probes for Eomes, perforin, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

DN T-bet might promiscuously coinhibit Eomes (Fig. 1A), because the specificity of T-box factors partly resides in the T-box domain (11, 16). We found DN T-bet RV equally, albeit incompletely, antagonized the ability of full-length T-bet or Eomes RV to induce IFN- $\gamma$  in developing T<sub>H</sub>2 cells (9). Thus, Eomes appears to complement T-bet in mediating induction of IFN- $\gamma$  in T cells and may play a key role in the effector differentiation of CD8<sup>+</sup> T cells.

In addition to secretion of IFN- $\gamma$ , the other major effector function of CD8<sup>+</sup> T cells is the ability to lyse target cells by using granules containing perforin and granzymes. We found Eomes, perforin, and granzyme B to be coordinately induced in activated NK cells and CD8<sup>+</sup> T cells (Fig. 2A), two lineages that have been suggested to exhibit substantial cytotoxic function in the absence of T-bet (3). By contrast, activated CD4<sup>+</sup> T cells express lower levels of Eomes, perforin, and granzyme B. We also detected substantial Eomes expression in vivo. CD8<sup>+</sup> T cells from mice infected for 6 days with lymphocytic chorio-


meningitis virus (LCMV), a potent inducer of cytolytic effector cells (17–19), expressed high levels of Eomes mRNA compared with CD8<sup>+</sup> T cells from uninfected mice, or CD4<sup>+</sup> T cells from the infected animals (Fig. 2B). Thus, Eomes appeared to be expressed in cells undergoing cytolytic effector CD8<sup>+</sup> T cell development, in vitro and in vivo.

To determine whether Eomes plays a causal role in T-bet-independent cytolytic effector differentiation, we analyzed activated CD8<sup>+</sup> T cells from *T-bet*<sup>+/+</sup> and *T-bet*<sup>-/-</sup> mice. We found that T-bet deficiency resulted in a modest but reproducible defect in granzyme B induction, as assessed by antibody staining and flow cytometry (Fig. 2C). Introduction of DN Eomes or DN T-bet RV into either *T-bet*<sup>+/+</sup> or *T-bet*<sup>-/-</sup> cells led to a significantly greater defect in granzyme B expression than simple *T-bet* gene deletion (Fig. 2C). In addition, we introduced DN Eomes RV into differentiating effector CD8<sup>+</sup> T cells from LCMV peptide-specific TCR transgenic mice (20). Effector cells transduced with DN Eomes exhibited a substantial defect in killing of peptide-pulsed target cells compared with cells transduced with control RV (Fig. 2D).

These findings suggested that Eomes, perhaps in concert with T-bet, was required for the lytic effector program seen in CD8<sup>+</sup> T cells. Although *Eomes*<sup>-/-</sup> mice die in embryogenesis (12, 21), we attempted to explore the necessity of Eomes in effector differentiation by examining haplo-insufficient mice, whose peripheral T cell composition appears normal (9). Splenocytes from littermate *Eomes*<sup>+</sup> and *Eomes*<sup>+/-</sup> mice (21) were stimulated via the TCR for 3 days. Cells from *Eomes*<sup>+</sup> mice indeed exhibited reduction in Eomes mRNA (Fig. 2E), and this partial knockdown of Eomes levels was accompanied by a substantial reduction in perforin mRNA (Fig. 2E). A similar defect was observed when purified CD8<sup>+</sup> T cells were used (15). We detected only minimal loss of IFN- $\gamma$  expression in CD8<sup>+</sup> T cells from *Eomes*<sup>+</sup> mice, possibly owing to the partial knockdown and redundancy from the actions of T-bet (15).

To further establish specific causality between Eomes and the induction of cytolytic genes, we examined the effect of overexpression of Eomes or T-bet in developing T<sub>H</sub>2 cells. Eomes and, to a lesser extent, T-bet RV were each sufficient to induce perforin (Fig. 3A) and granzyme B (Fig. 3B) mRNA, as well as granzyme B protein (Fig. 3C). By contrast to the lytic genes, T-bet appeared to be superior to Eomes at induction of IL-12R $\beta$ 2 (9), which suggests that each factor had some level of specificity in its target genes. Some caution must of course be used in interpreting the effects achieved with overexpression, because amounts of RV mRNA may exceed endogenous levels (9). Nonetheless, the collective results presented here suggest that Eomes is a critical factor in directing lytic effector differentiation of CD8<sup>+</sup> T cells.

Elegant genetic studies have recently illustrated that the transcriptional control of cellular immunity, at least partially, transcends the functions of T-bet (3, 22). By virtue of its homology to T-bet, its pattern of expression and, in particular, the results of genetic manipulation, Eomesodermin appears to be a key component of this elusive pathway. The general agreement between the results of dominant negative experiments, partial knockdown of Eomes, and ectopic overexpression suggests that Eomes is not simply an inducer of IFN- $\gamma$  but also appears to be critical for invoking the characteristics of the cytolytic effector lineage. Eomes, thus, appears to complement the role of T-bet in governing cellular immunity by providing redundancy and, quite likely, cooperativity in the induction of effector genes of T cells and NK cells. Future experiments, such as conditional gene deletion, should help address the issue of relative necessity of Eomes and T-bet in various in vivo immune responses or determine whether further redundancy and robustness of such pathways underlie our evolutionary success in mediating immunity to infection and tumors.



**Fig. 3.** Eomesodermin is sufficient to invoke cytotoxic T cell gene expression. (A and B) CD8-depleted BALB/c splenocytes were stimulated in T<sub>H</sub>2 conditions for 24 hours, and then transduced with control GFP RV, T-bet GFP RV, or Eomes GFP RV. Cells were recultured in T<sub>H</sub>2 conditions for 4 days before sorting for GFP and CD4 expression. RNA was extracted from sorted cells and analyzed by Northern blotting with specific probes for perforin (A), granzyme B (B), and  $\beta$ -actin (A and B). (C) Eomes is sufficient to induce granzyme B protein expression in developing T<sub>H</sub>2 cells. CD8-depleted BALB/c splenocytes were stimulated in T<sub>H</sub>2 conditions for 24 hours, and then transduced with control GFP RV, T-bet GFP RV, or Eomes GFP RV. Cells were recultured in T<sub>H</sub>2 conditions for 4 days before analysis of GFP, CD4, and granzyme B expression by flow cytometry. Granzyme B staining among CD4<sup>+</sup>GFP<sup>+</sup> events is shown. Filled gray histogram designates control RV, open gray histogram designates T-bet RV, and open black histogram designates Eomes RV. Relative to control, the increase in mean fluorescence intensity induced by T-bet and Eomes was 1.8-fold and 3.8-fold, respectively.

References and Notes

1. W. Zheng, R. A. Flavell, *Cell* **89**, 587 (1997).
2. S. J. Szabo et al., *Cell* **100**, 655 (2000).
3. S. J. Szabo et al., *Science* **295**, 338 (2002).
4. A. C. Mullen et al., *Science* **292**, 1907 (2001).
5. A. C. Mullen et al., *Nature Immunol.* **3**, 652 (2002).
6. J. D. Fontenot, M. A. Gavin, A. Y. Rudensky, *Nature Immunol.* **4**, 330 (2003).
7. S. Hori, T. Nomura, S. Sakaguchi, *Science* **299**, 1057 (2003).
8. R. Khattri, T. Cox, S. A. Yasayko, F. Ramsdell, *Nature Immunol.* **4**, 337 (2003).
9. Supporting online material is available on Science online.
10. N. Cereb, G. A. Martins, S. L. Reiner, S. Y. Yang, manuscript in preparation.
11. K. Ryan, N. Garrett, A. Mitchell, J. B. Gurdon, *Cell* **87**, 989 (1996).
12. A. P. Russ et al., *Nature* **404**, 95 (2000).
13. C. H. Yi et al., *Genomics* **55**, 10 (1999).
14. A. C. Horton, J. J. Gibson-Brown, *J. Exp. Zool.* **294**, 112 (2002).
15. S. L. Reiner, unpublished results.
16. F. L. Conlon, L. Fairclough, B. M. Price, E. S. Casey, J. C. Smith, *Development* **128**, 3749 (2001).
17. S. M. Kaech, S. Hemby, E. Kersh, R. Ahmed, *Cell* **111**, 837 (2002).
18. E. J. Wherry et al., *Nature Immunol.* **4**, 225 (2003).
19. D. J. Shedlock, H. Shen, *Science* **300**, 337 (2003).
20. H. Pircher, K. Burki, R. Lang, H. Hengartner, R. M. Zinkernagel, *Nature* **342**, 559 (1989).
21. C. Mao, J. Rossant, manuscript in preparation.
22. S. L. Peng, S. J. Szabo, L. H. Glimcher, *Proc. Natl. Acad. Sci. U.S.A.* **99**, 5545 (2002).
23. We are grateful to N. Killeen, K. Ryan, and C. Gasink for critical insights; K. Sykes for exceptional assistance; and M. Bogumil, W. DeMuth, K. Foulds, M. Gohil, R. Jones, M. Maldonado, M. Mooney, V. Prideaux, J. Rathmell, A. Russ, D. Shedlock, R. Vonderheide, and L. Zenewicz for generous help. This work was supported by grants from the NIH (AI-042370 and GM-07229) and the generosity of Leonard and Madlyn Abramson.

**Supporting Online Material**  
[www.sciencemag.org/cgi/content/full/302/5647/1041/DC1](http://www.sciencemag.org/cgi/content/full/302/5647/1041/DC1)  
 Materials and Methods  
 Figs. S1 to S11  
 References and Notes

6 August 2003; accepted 10 September 2003

# ERRATUM

post date 9 January 2004

**REPORTS:** "Control of effector CD8<sup>+</sup> T cell function by the transcription factor *Eomesodermin*" by E. L. Pearce *et al.* (7 Nov. 2003, p. 1041). On p. 1043, in the third paragraph of the middle column, superscript symbols were removed, which changed the meaning of three sentences. The correct sentences are as follows: "Splenocytes from littermate *Eomes*<sup>+/+</sup> and *Eomes*<sup>+/-</sup> mice (27) were stimulated via the TCR for 3 days. Cells from *Eomes*<sup>+/-</sup> mice indeed exhibited reduction in *Eomes* mRNA (Fig. 2E), and this partial knockdown of *Eomes* levels was accompanied by a substantial reduction in perforin mRNA (Fig. 2E)... We detected only minimal loss of IFN- $\gamma$  expression in CD8<sup>+</sup> T cells from *Eomes*<sup>+/-</sup> mice, possibly owing to the partial knockdown and redundancy from the actions of T-bet (15)."



**Control of Effector CD8<sup>+</sup> T Cell Function by the Transcription Factor *Eomesodermin***

Erika L. Pearce, Alan C. Mullen, Gislaine A. Martins, Connie M. Krawczyk, Anne S. Hutchins, Valerie P. Zediak, Monica Banica, Catherine B. DiCioccio, Darrick A. Gross, Chai-an Mao, Hao Shen, Nezhir Cereb, Soo Y. Yang, Tullia Lindsten, Janet Rossant, Christopher A. Hunter and Steven L. Reiner (November 6, 2003)  
*Science* **302** (5647), 1041-1043. [doi: 10.1126/science.1090148]

Editor's Summary

---

This copy is for your personal, non-commercial use only.

---

- Article Tools** Visit the online version of this article to access the personalization and article tools:  
<http://science.sciencemag.org/content/302/5647/1041>
- Permissions** Obtain information about reproducing this article:  
<http://www.sciencemag.org/about/permissions.dtl>

*Science* (print ISSN 0036-8075; online ISSN 1095-9203) is published weekly, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. Copyright 2016 by the American Association for the Advancement of Science; all rights reserved. The title *Science* is a registered trademark of AAAS.